Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial

Alexandra J. Lansky(Queen Mary University of London), Andreas Baumbach(Queen Mary University of London), Andrzej Ochała(Medical University of Silesia), Lene Holmvang(Rigshospitalet), Richard Anderson(University Hospital of Wales), Luc Maillard, Paul Knaapen(Amsterdam University Medical Centers), William Wijns(Ollscoil na Gaillimhe – University of Galway), Hölger Thiele(Leipzig Heart Institute), Paweł Buszman(American Heart of Poland), Harald Rittger(Klinikum Fürth), Sérgio Berti, Niels van Royen(Radboud University Nijmegen), Christoph Naber(Elisabeth-Krankenhaus Essen), Henning Kelbæk(Zealand University Hospital), Christian Valina(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Emanuele Barbato(CTO Andrea Alesini), Ton Slagboom(OLVG), Salvatore Brugaletta(Hospital Clínic de Barcelona), Volker Schächinger(Klinikum Fulda), Ming Zheng(Chinese Academy of Agricultural Sciences), Bo Xu(Jiangnan University), Tom Johnson(University Hospitals Bristol NHS Foundation Trust), Luc Janssens(Imelda Hospital), Gábor G. Tóth(Medical University of Graz), Georgios J. Vlachojannis(Maasstad Ziekenhuis), Marie‐Angèle Morel(Unknown), Karin Arkenbout(Tergooi)
The Lancet
September 1, 2018
Cited by 61


Related Papers